Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092792 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02092792 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 42 participants.
The verdict
NCT02092792, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and PK of escalating doses of DLYE5953A administered to patients with incurable, locally advanced, or metastatic solid malignancy that has progressed on standard therapy. The Phase I study consists of two stages: Stage 1 dose-escalation and Stage 2 expansion in selected patients. In Stage 1, a 3 + 3 dose-escalation design will be used to examine the safety, tolerability, and PK of increasing doses of DLYE5953A. In Stage 2, patients will be enrolled to further characterize the safety, tolerability, and PK of the proposed dose and schedule for future studies.
Interventions
- DRUG DLYE5953A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092792
The ClinicalTrials.gov registry entry for NCT02092792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DLYE5953A is the first listed.
NCT02092792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02092792 about?
NCT02092792 is a clinical study titled "A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors". This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and PK of escalating doses of DLYE5953A administered to patients with incurable, locally advanced, or metastatic solid malignancy that has progressed on standard therapy. The Phase I study consists of two stages:...
What is the current status of trial NCT02092792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2014-04-01. Estimated completion is 2017-07-10.
What interventions are being tested in trial NCT02092792?
The interventions under investigation include: DLYE5953A (DRUG).
Who is sponsoring clinical trial NCT02092792?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.